Biotech Values

[biomaven0]

>>(ALK+) advanced non-small cell lung cancer (NSCLC) treated with first-line Zykadia (ceritinib) had a median progression-free survival (PFS) of 16.6 months

Worth pointing out that that PFS is about the same as for 2nd-line brigatinib (15.6 months) after first failing on crizotinib.

There are only two horses left in this race - Alectinib and the somewhat better Brigatinib. Alectinib of course has a lead to market of a year or more and more marketing muscle. But Briga is the better drug, particularly after criz failure (because of brain mets).